Evidence map›Paper›PMID 31112258›Full record

ArticleJAMA2019

Trends in Levels of Lipids and Apolipoprotein B in US Youths Aged 6 to 19 Years, 1999-2016.

Amanda M Perak, Hongyan Ning, Brian K Kit, Sarah D de Ferranti, Linda V Van Horn, John T Wilkins, Donald M Lloyd-Jones

Open access · bronzeAbstract read
In one paragraph

Article in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 3 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Amanda M PerakDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Hongyan NingDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Brian K KitNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Sarah D de FerrantiDepartment of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Linda V Van HornDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
John T WilkinsDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Donald M Lloyd-JonesDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Northwestern University · USHarvard University · USNational Heart Lung and Blood Institute · USRobert H. Lurie Comprehensive Cancer Center of Northwestern University

Funding

RESEARCH TRAINING IN CVD EPIDEMIOLOGY AND PREVENTIONT32HL069771 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Mercedes Renee Carnethon · 2003 to 2026
$5.9M
Response of the Gut Microbiome and Circulating Metabolome to Diet Intervention in Young Children: Ancillary Study to the Keeping Ideal Cardiovascular Health Family Intervention Trial (KIDFIT)K23HL145101 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI MARMA, AMANDA K · 2019 to 2023
$948k
Iterative development and pilot testing of a mobile health intervention to increase postpartum weight loss in women at increased risk for cardiometabolic diseaseK23HL133604 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI NICKLAS, JACINDA MAWSON · 2016 to 2019
$769k
NHLBI NIH HHS K23 HL133604NHLBI NIH HHS K23 HL145101NHLBI NIH HHS T32 HL069771
6 · The paper itself

Abstract

Importance: Favorable trends occurred in the lipid levels of US youths through 2010, but these trends may be altered by ongoing changes in the food supply, obesity prevalence, and other factors. Objective: To analyze trends in levels of lipids and apolipoprotein B in US youths during 18 years from 1999 through 2016. Design, Setting, and Participants: Serial cross-sectional analysis of US population-weighted data for youths aged 6 to 19 years from the National Health and Nutrition Examination Surveys for 1999 through 2016. Linear temporal trends were analyzed using multivariable regression models with regression coefficients (β) reported as change per 1 year. Exposures: Survey year; examined periods spanned 10 to 18 years based on data availability. Main Outcomes and Measures: Age- and race/ethnicity-adjusted mean levels of high-density lipoprotein (HDL), non-HDL, and total cholesterol. Among fasting adolescents (aged 12-19 years), mean levels of low-density lipoprotein cholesterol, geometric mean levels of triglycerides, and mean levels of apolipoprotein B. Prevalence of ideal and adverse (vs borderline) levels of lipids and apolipoprotein B per pediatric lipid guidelines. Results: In total, 26 047 youths were included (weighted mean age, 12.4 years; female, 51%). Among all youths, the adjusted mean total cholesterol level declined from 164 mg/dL (95% CI, 161 to 167 mg/dL) in 1999-2000 to 155 mg/dL (95% CI, 154 to 157 mg/dL) in 2015-2016 (β for linear trend, -0.6 mg/dL [95% CI, -0.7 to -0.4 mg/dL] per year). Adjusted mean HDL cholesterol level increased from 52.5 mg/dL (95% CI, 51.7 to 53.3 mg/dL) in 2007-2008 to 55.0 mg/dL (95% CI, 53.8 to 56.3 mg/dL) in 2015-2016 (β, 0.2 mg/dL [95% CI, 0.1 to 0.4 mg/dL] per year) and non-HDL cholesterol decreased from 108 mg/dL (95% CI, 106 to 110 mg/dL) to 100 mg/dL (95% CI, 99 to 102 mg/dL) during the same years (β, -0.9 mg/dL [95% CI, -1.2 to -0.6 mg/dL] per year). Among fasting adolescents, geometric mean levels of triglycerides declined from 78 mg/dL (95% CI, 74 to 82 mg/dL) in 1999-2000 to 63 mg/dL (95% CI, 58 to 68 mg/dL) in 2013-2014 (log-transformed β, -0.015 [95% CI, -0.020 to -0.010] per year), mean levels of low-density lipoprotein cholesterol declined from 92 mg/dL (95% CI, 89 to 95 mg/dL) to 86 mg/dL (95% CI, 83 to 90 mg/dL) during the same years (β, -0.4 mg/dL [95% CI, -0.7 to -0.2 mg/dL] per year), and mean levels of apolipoprotein B declined from 70 mg/dL (95% CI, 68 to 72 mg/dL) in 2005-2006 to 67 mg/dL (95% CI, 65 to 70 mg/dL) in 2013-2014 (β, -0.4 mg/dL [95% CI, -0.7 to -0.04 mg/dL] per year). Favorable trends were generally also observed in the prevalence of ideal and adverse levels. By the end of the study period, 51.4% (95% CI, 48.5% to 54.2%) of all youths had ideal levels for HDL, non-HDL, and total cholesterol; among adolescents, 46.8% (95% CI, 40.9% to 52.6%) had ideal levels for all lipids and apolipoprotein B, whereas 15.2% (95% CI, 13.1% to 17.3%) of children aged 6 to 11 years and 25.2% (95% CI, 22.2% to 28.2%) of adolescents aged 12 to 19 years had at least 1 adverse level. Conclusions and Relevance: Between 1999 and 2016, favorable trends were observed in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years.

Indexed as

AdolescentApolipoproteins BChildCholesterolCross-Sectional StudiesFemaleHumansHyperlipidemiasLipoproteinsMalePrevalenceTriglyceridesUnited StatesYoung AdultApolipoproteins BCholesterolLipoproteinsTriglycerides

Identifiers

PMID31112258
PMCPMC6537842
OpenAlexW2944839479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.